Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20128726 | 1.00 | KDM4E (0.43) | KDM4EALDH1A1MEN1KMT2AGAA | |
| SCHEMBL20133152 | 1.00 | KDM4E (0.43) | KDM4EALDH1A1MEN1KMT2AGAA | |
| SCHEMBL27408407 | 1.00 | KDM4E (0.43) | KDM4EALDH1A1MEN1KMT2AGAA | |
| SCHEMBL4547565 | 0.96 | KDM4E (0.38) | KDM4EALDH1A1MEN1KMT2AGAA | |
| SCHEMBL20993534 | 0.91 | KDM4E (0.38) | KDM4EALDH1A1MEN1KMT2AGAA | |
| SCHEMBL20234227 | 0.89 | KDM4E (0.37) | KDM4EALDH1A1MEN1KMT2AGAA | |
| SCHEMBL21316648 | 0.87 | KDM4E (0.42) | KDM4EALDH1A1MEN1KMT2AGAA | |
| SCHEMBL12980779 | 0.87 | KDM4E (0.38) | KDM4EALDH1A1MEN1KMT2AGAA | |
| SCHEMBL10046329 | 0.87 | KDM4E (0.38) | KDM4EALDH1A1MEN1KMT2AGAA | |
| SCHEMBL23483122 | 0.86 | MEN1 (0.33) | KDM4EALDH1A1MEN1KMT2ACES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239863-A1 | GIP RECEPTOR AGONIST AND USE THEREOF | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240239863-A1 | GIP RECEPTOR AGONIST AND USE THEREOF | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240209439-A1 | NUCLEOTIDE ANALOGUE FOR SEQUENCING | BGI SHENZHEN (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240209028-A1 | CNP COMPOUNDS | NOVO NORDISK A/S (DK) | 2024-06-27 | — | — | US | disclosed |
| US-12018057-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | JANSSEN BIOTECH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018057-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | JANSSEN BIOTECH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| WO-2024094747-A1 | CNP COMPOUNDS | NOVO NORDISK A/S (DK) | 2024-05-10 | — | — | WO | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11753443-B2 | Conjugated hepcidin mimetics | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20110213131-A1 | Method of Acylating a Peptide or Protein | NOVO NORDISK A/S (DK) | 2011-09-01 | — | — | US | disclosed |
| US-20100317057-A1 | SEMI-RECOMBINANT PREPARATION OF GLP-1 ANALOGUES | NOVO NORDISK A/S (DK) | 2010-12-16 | — | — | US | disclosed |
| US-20100179304-A1 | Somatostatin-Dopamine Chimeric analogs | IPSEN PHARMA S.A.S. (FR) | 2010-07-15 | — | — | US | disclosed |
| US-20100179304-A1 | Somatostatin-Dopamine Chimeric analogs | IPSEN PHARMA S.A.S. (FR) | 2010-07-15 | — | — | US | disclosed |
| US-20090275501-A1 | Somatostatin-dopamine chimeric analogs | IPSEN PHARMA S.A.S. (FR) | 2009-11-05 | — | — | US | disclosed |
| US-20090275501-A1 | Somatostatin-dopamine chimeric analogs | IPSEN PHARMA S.A.S. (FR) | 2009-11-05 | — | — | US | disclosed |
| US-7579435-B2 | Somatostatin-dopamine chimeric analogs | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2009-08-25 | — | — | US | disclosed |
| US-7579435-B2 | Somatostatin-dopamine chimeric analogs | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2009-08-25 | — | — | US | disclosed |
| US-7572883-B2 | Somatostatin-dopamine chimeric analogs | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2009-08-11 | — | — | US | disclosed |
| US-7572883-B2 | Somatostatin-dopamine chimeric analogs | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2009-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209439-A1 | NUCLEOTIDE ANALOGUE FOR SEQUENCING | NT5C3B, NT5E, NUDT1 | KDM4E 2062/4885ALDH1A1 1433/4885MEN1 1993/4885 |
| US-20240209028-A1 | CNP COMPOUNDS | NPPA, NPR1, NPR3 | KDM4E 4814/4885ALDH1A1 4267/4885MEN1 1316/4885 |
| US-20230357199-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | KDM4E 3553/4885ALDH1A1 2338/4885MEN1 1035/4885 |
| US-20100179304-A1 | Somatostatin-Dopamine Chimeric analogs | SSTR3, SLC6A3, PRLHR | KDM4E 3745/4885ALDH1A1 2606/4885MEN1 1131/4885 |
| US-11753443-B2 | Conjugated hepcidin mimetics | HAMP, VIP, HDGF | KDM4E 4176/4885ALDH1A1 3616/4885MEN1 277/4885 |
| US-20110213131-A1 | Method of Acylating a Peptide or Protein | DNPEP, PTMA, ANPEP | KDM4E 4619/4885ALDH1A1 3829/4885MEN1 2834/4885 |
| US-20240239863-A1 | GIP RECEPTOR AGONIST AND USE THEREOF | GIPR, GLP1R, GPR119 | KDM4E 3791/4885ALDH1A1 4748/4885MEN1 1431/4885 |
| US-12018057-B2 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | IL23R, IL1RN, VIP | KDM4E 4705/4885ALDH1A1 4574/4885MEN1 3503/4885 |
| US-20090275501-A1 | Somatostatin-dopamine chimeric analogs | SSTR3, SLC6A3, PRLHR | KDM4E 3745/4885ALDH1A1 2606/4885MEN1 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.